3,000
Participants
Start Date
February 27, 2018
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2035
Treatment Recommendation Surveys
Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.
7-gene biosignature
Ordering the 7-gene biosignature assay (DCISionRT) as a part of routine care for DCIS is a prerequisite (inclusion criterion) for the study. The study is not designed to determine the efficacy of the assay, rather it is designed to meausre the impact of the assay results on treatment decisions for patients with DCIS.
RECRUITING
Maimonides Cancer Center, Brooklyn
RECRUITING
St. Joseph's Hospital Tampa, Tampa
RECRUITING
Nashville Breast Center, Nashville
RECRUITING
The Ohio State University, Columbus
RECRUITING
Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
RECRUITING
Cleveland Clinic Akron General, Akron
RECRUITING
Comprehensive Breast Care, Troy
RECRUITING
Baylor College of Medicine, Houston
RECRUITING
University of Colorado Denver, Aurora
RECRUITING
UC Health - Memorial Hospital, Colorado Springs, Colorado Springs
RECRUITING
Arizona Center for Cancer Care, Phoenix
RECRUITING
Mills-Peninsula Medical Center, San Mateo
RECRUITING
Sutter Institute for Medical Research, Sacramento
RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
Dana-Farber/Brigham and Women's Cancer Center at South Shore, South Weymouth
Lead Sponsor
PreludeDx
INDUSTRY